SynthesisBiological psychiatry. Cognitive neuroscience and neuroimaging2025
Glutamatergic Modulation of Brain Function in Psychosis: A Systematic Review of Neuroimaging Studies.
Synthesis in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Continuous monitoring of glutamate using electroactive templated polymers as synthetic molecular receptors.The Analyst · 2026Article
- From synapse to system: mechanistic pathways of neural signaling dysfunction in psychiatric disorders.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant dopamine and glutamate signaling are implicated in the pathophysiology of schizophrenia. Existing treatments primarily target dopamine pathways underlying positive symptoms but have relatively little effect on cognitive and negative symptoms. Glutamatergic modulators may treat the latter symptom domains, and neuroimaging studies have the potential to identify therapeutic mechanisms. We conducted a systematic review to examine functional neuroimaging studies of glutamatergic modulators in psychosis and determine whether these agents alter brain activity, chemistry, or functional connectivity and whether such changes map onto clinical outcomes. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO: CRD42024549120), MEDLINE, Embase, and PsycInfo were searched from inception to June 2024 for studies administering pharmacologic glutamate modulators to individuals with psychosis, using functional neuroimaging (proton magnetic resonance spectroscopy [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.